<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126320</url>
  </required_header>
  <id_info>
    <org_study_id>HST -AG -02</org_study_id>
    <nct_id>NCT01126320</nct_id>
  </id_info>
  <brief_title>Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated Patients Using the AnapnoGuard System</brief_title>
  <official_title>Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated ICU Patients Using the AnapnoGuard System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospitech Respiration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospitech Respiration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventilator Associated Pneumonia (VAP) is a common complication experienced by mechanically
      ventilated patients and within the framework of Respiratory Intensive Care Units. The
      AnapnoGuard system, developed by Hospitech Respiration Ltd. is a ventilation guard system
      that includes a number of unique characteristics. This study was designed to test the
      frequency VAP in mechanically ventilated ICU patients using the AnapnoGuard System.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAP occurence</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events occurence</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>AnapnoGuard 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Respiratory guard system during mechanical ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>routine mechanical ventilator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AnapnoGuard 100,</intervention_name>
    <description>Respiratory guard system during mechanical ventilation with routine mechanical ventilator</description>
    <arm_group_label>AnapnoGuard 100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>routine mechanical ventilator</intervention_name>
    <description>routine mechanical ventilation</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICU patients;

          -  Patient was connected to AnapnoGuard system up to six hours from intubation;

          -  Age - above 18.

        Exclusion Criteria:

          -  Pneumonia;

          -  Aspiration Pneumonia;

          -  Chronic or Severe Pneumonia;

          -  Chronic Obstructive Pulmonary Disease (COPD) requiring permanent home-based antibiotic
             treatment;

          -  Interstitial Lung Disease (ILD);

          -  Post Lung Transplant State;

          -  Immunosuppression.

          -  Patients ventilated in prone position

          -  Patient who was ventilated 3 months prior to being enrolled in the study

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron Bar Lavi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RAMBAM Medical Center, Haifa Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RAMBAM Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

